Recent Updates
Recently added Catalysts

Serum containing Avonex

Phase 1

Multiple Sclerosis | Small molecule | Immunology |Biogen Inc.|Last Updated: Jun 4, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment96
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00913250A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy VolunteersPHASE1 COMPLETED 96Aug 1, 2003Oct 1, 2003Jun 4, 2009 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To demonstrate the bioequivalence of a serum-free Avonex and a serum-containing AVONEX® when given intramuscularly (IM) to healthy volunteers.
Study duration is 72 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Sequence 1EXPERIMENTALSerum containing Avonex followed by serum free Avonex
Sequence 2EXPERIMENTALSerum free Avonex followed by serum containing Avonex
Interventions
NameTypeDescription
Serum containing AvonexDRUG60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
Serum Free AvonexDRUG60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy Volunteers Exclusion Criteria: * History of severe allergic or anaphylactic reactions * History of hypersensitivity to acetaminophen (paracetamol), ibuprofen, or codeine. * Known allergy to dry natural rubber * History of seizure disorder or unexplained blackouts * H...

Unlock Eligibility Criteria